Eisai Deal Puts Epizyme In Position To Advance Lead Program

Deal with Eisai on epigenetic enzymes is collaborative, whereas in recent tie up with GSK, Epizyme gave up control of development and commercialization of select histone methyltransferases.

More from Archive

More from Pink Sheet